FIGURE 6.
pEDN and uEDN concentrations increase prior to relapse on benralizumab. pEDN concentrations (purple circles, left y-axis) and uEDN concentrations (orange squares, left y-axis) prior to development of clinical symptoms related to HES disease relapse (black arrow) and/or prior to a rise in AEC (red diamonds, right y-axis)